Back to Search
JASON GOTLIB, M.D., M.S.
M.D., M.S.
Hematology (Internal Medicine) Physician
NPI: 1790827640IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology (Internal Medicine) PhysicianPrimary
Internal Medicine — Hematology
Code: 207RH0000X
A060833(CA)
Education
STANFORD UNIVERSITY SCHOOL OF MEDICINE
Class of 1995
Research & Publications (20)
A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes.
PMID 19006226·Am J Hematol·2009
3-trial
Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias.
PMID 18843283·Leukemia·2008
6-review
Chronic eosinophilic leukemia/hypereosinophilic syndrome.
PMID 18283783·Cancer Treat Res·2008
6-review
KIT mutations in mastocytosis and their potential as therapeutic targets.
PMID 16931294·Immunol Allergy Clin North Am·2006
6-review
Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
PMID 16781488·Best Pract Res Clin Haematol·2006
6-review
Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
PMID 15995322·Acta Haematol·2005
6-review
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
PMID 15972446·Blood·2005
5-case
Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
PMID 15610664·Curr Hematol Rep·2005
6-review
The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
PMID 15070659·Blood·2004
6-review
Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission.
PMID 19452323·Leuk Lymphoma·2009
5-case
Monoclonal antibodies against IREM-1: potential for targeted therapy of AML.
PMID 19440216·Leukemia·2009
7-preclinical
RNAi screen for rapid therapeutic target identification in leukemia patients.
PMID 19433805·Proc Natl Acad Sci U S A·2009
8-other
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens.
PMID 19363496·Nat Med·2009
8-other
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.
PMID 19237556·Proc Natl Acad Sci U S A·2009
7-preclinical
Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.
PMID 19131546·Blood·2009
8-other
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
PMID 18394555·Cancer Cell·2008
7-preclinical
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
PMID 18160667·Blood·2008
3-trial
Gene expression and pathway analysis of immune thrombocytopenic purpura.
PMID 18005267·Br J Haematol·2008
8-other
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
PMID 17728787·Leukemia·2008
8-other
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
PMID 17210175·Leuk Res·2007
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 875 BLAKE WILBUR DR RM 2327B
PALO ALTO, CA 94304 - Phone
- (650) 736-1253
Quick Facts
- NPI
- 1790827640
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 31
- Publications
- 20
Are you this provider?
Claim Your Profile